ArticleDiscover oncology2026
Systematic analyses to explore kinase gene set-based signature in glioma, in which WEE1 contributes to tumor progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesDespite the close association with patient clinical outcomes, dysregulated kinases in gliomas are not commonly used as clinical indicators. We aimed to identify a kinase-related gene signature for glioma patients that improves clinical risk-stratification.
methodsLeast absolute shrinkage and selection operator (LASSO) Cox regression analysis was conducted to identify kinase-related gene signature. The association between the risk model and patient survival, pathway activation, and immune suppression status was further explored. Additionally, cell proliferation and tumor formation assay were performed to evaluate the oncogenic roles of identified kinase gene.
resultsIn this study, we identified a 10-gene kinase signature in TCGA dataset that is significantly associated with poor overall survival (OS) in glioma patients. A consistent prediction ability for survival was further demonstrated in the CGGA dataset. In addition, the signature was significantly linked to malignant molecular signatures, such as IDH wild type and non-codeletion of 1p19q. Moreover, the high-risk group exhibited a wide array of oncogenic biological pathways. Interestingly, the result showed that the kinase-related signature is tightly linked with immune suppression signatures, including immune infiltration of MDSCs and Tregs, and expression of immunosuppressive genes. Functionally, the oncogenic roles of WEE1 in gliomas were validated.
conclusionsThe findings present a novel kinase-related gene signature with potential value for survival prediction in gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.